EC Number   |
Application |
Reference |
|---|
    6.3.4.2 | analysis |
fast assay allows the processing of a large number of samples |
648996 |
| 6.3.4.2 | drug development |
CTP is a recognized target for the development of anticancer, antiviral, and antiprotozoal agents |
702613 |
| 6.3.4.2 | drug development |
daily injection of acivicin in trypanosome-infected mice suppresses the infection up to one month without any significant loss of weight. Experiments with cultured bloodstream Trypanosoma brucei shows that acivicin is trypanocidal if present at 0.001 nM concentration for at least 4 d. Acivicin may qualify as a drug with desirable properties, i.e. cure within 7 d, according to the current Target Product Profiles of WHO and DNDi |
674786 |
| 6.3.4.2 | drug development |
modifying 2-aminopurine or 2-aminopurine riboside may serve as an effective strategy for developing CTPS inhibitors |
674909 |
| 6.3.4.2 | drug development |
structure serves as a basis for structure-based design of anti-proliferative inhibitors |
671115 |
| 6.3.4.2 | medicine |
glutamine deficiency induces CTPS cytoophidia in human Huh-7 cells. CTPS cytoophidia are found in various human cancers and some noncancerous tissues. Among 203 tissue samples of hepatocellular carcinoma, 28% exhibited many cytoophidia, whereas no cytoophidia are detected in adjacent noncancerous hepatocytes for all samples |
744848 |
| 6.3.4.2 | medicine |
the enzyme is an target for treatment of African sleeping sickness because the trypanosomes, unlike mammalian cells, cannot compensate for the inhibition of CTP synthetase by the salvage of cytidine. The CTP synthetase inhibitors 6-diazo-5-oxo-L-norleucine and alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid reduce the parasite CTP level even further and inhibit trypanosome proliferation in vitro and in Trypanosoma brucei-infected mice |
648972 |
